RxDoctor Payments Data

Niel Rasmussen, MD

Family Medicine · Headland, ALNPI 1174560916

Payments from drug & device makers

$1,051in general payments, 2019–2025

Across 60 payments — averaging $17.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$438
  • Lilly USA, LLC$176
  • AstraZeneca$119
  • Exact Sciences$73
  • Pfizer$56
  • Amgen$51
  • plus $138 from 6 others

What the payments were for

  • Speaking & faculty fees$202%
  • Food & beverage$1,03198%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,051 in reported general payments places this provider in the 55th percentile of 1,680 family medicine providers in Alabama.

See all family medicine providers in Alabama

Medicare billing

Part B allowed, 2024
$252,621
Medicare patients
404
Services billed
5,917

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin263$272,894
MounjaroTirzepatide189$210,499
EliquisApixaban114$139,967
OzempicSemaglutide129$135,034
FarxigaDapagliflozin Propanediol87$78,931
Humira(Cf) PenAdalimumab11$72,932
TrulicityDulaglutide62$72,567
Trelegy ElliptaFluticasone/Umeclidin/Vilanter62$48,811
JanuviaSitagliptin Phosphate28$42,213
RybelsusSemaglutide41$41,447
XareltoRivaroxaban30$40,602
LinzessLinaclotide44$35,824
ShingrixVaricella-Zoster Ge/As01b/Pf150$31,212
ArexvyRsvpref3 Antigen/As01e/Pf90$26,754
MyrbetriqMirabegron21$24,922

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$176$283,065251 claims
Novo NordiskOzempic, Rybelsus$438$176,481170 claims
PfizerEliquis, Abrysvo$56$149,435145 claims
GSKTrelegy Ellipta, Shingrix, Arexvy, Breo Ellipta, Arnuity Ellipta$45$148,035405 claims
AstraZenecaFarxiga, Symbicort$119$89,136128 claims
MerckJanuvia, Janumet Xr$17$57,31941 claims
Johnson & JohnsonXarelto$18$40,60230 claims
AbbVieLinzess$18$35,82444 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,680 family medicine providers in Alabama.

Other family medicine in Headland

See the full list for Alabama

Where these figures come from

Is this you, or does something look wrong? →